BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brouwers MCGJ, Simons N, Stehouwer CDA, Isaacs A. Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality. Diabetologia 2020;63:253-60. [PMID: 31713012 DOI: 10.1007/s00125-019-05024-3] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Klisic A, Kavaric N, Ninic A, Kotur-Stevuljevic J. Oxidative stress and cardiometabolic biomarkers in patients with non-alcoholic fatty liver disease. Sci Rep 2021;11:18455. [PMID: 34531465 DOI: 10.1038/s41598-021-97686-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Dai W, Zhang Z, Zhao S. The Risk of Type 2 Diabetes and Coronary Artery Disease in Non-obese Patients With Non-alcoholic Fatty Liver Disease: A Cohort Study. Front Cardiovasc Med 2021;8:680664. [PMID: 34490362 DOI: 10.3389/fcvm.2021.680664] [Reference Citation Analysis]
3 Sun HJ, Wu ZY, Nie XW, Bian JS. The Role of H2S in the Metabolism of Glucose and Lipids. Adv Exp Med Biol 2021;1315:51-66. [PMID: 34302688 DOI: 10.1007/978-981-16-0991-6_3] [Reference Citation Analysis]
4 Møller S, Kimer N, Kronborg T, Grandt J, Hove JD, Barløse M, Gluud LL. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Overlapping Mechanisms. Semin Liver Dis 2021;41:235-47. [PMID: 33992031 DOI: 10.1055/s-0041-1725022] [Reference Citation Analysis]
5 Caussy C, Aubin A, Loomba R. The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk. Curr Diab Rep 2021;21:15. [PMID: 33742318 DOI: 10.1007/s11892-021-01383-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Abenavoli L, Procopio AC, Medić-Stojanoska M, Luzza F. Non-alcoholic fatty liver disease and primary care physicians. Minerva Gastroenterol Dietol 2020;66:4-5. [PMID: 32283879 DOI: 10.23736/S1121-421X.20.02666-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
7 Tanase DM, Gosav EM, Costea CF, Ciocoiu M, Lacatusu CM, Maranduca MA, Ouatu A, Floria M. The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD).J Diabetes Res. 2020;2020:3920196. [PMID: 32832560 DOI: 10.1155/2020/3920196] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
8 Lee CO, Li HL, Tsoi MF, Cheung CL, Cheung BMY. Association between the liver fat score (LFS) and cardiovascular diseases in the national health and nutrition examination survey 1999-2016. Ann Med 2021;53:1065-73. [PMID: 34184611 DOI: 10.1080/07853890.2021.1943514] [Reference Citation Analysis]
9 Bowden Davies KA, Norman JA, Thompson A, Mitchell KL, Harrold JA, Halford JCG, Wilding JPH, Kemp GJ, Cuthbertson DJ, Sprung VS. Short-Term Physical Inactivity Induces Endothelial Dysfunction. Front Physiol 2021;12:659834. [PMID: 33897466 DOI: 10.3389/fphys.2021.659834] [Reference Citation Analysis]
10 Dong M, Liu S, Wang M, Wang Y, Xin Y, Xuan S. Relationship between AGT rs2493132 polymorphism and the risk of coronary artery disease in patients with NAFLD in the Chinese Han population. J Int Med Res 2021;49:3000605211019263. [PMID: 34275374 DOI: 10.1177/03000605211019263] [Reference Citation Analysis]
11 Hagström H, Kechagias S, Ekstedt M. Risk for hepatic and extra-hepatic outcomes in nonalcoholic fatty liver disease. J Intern Med 2021. [PMID: 34118091 DOI: 10.1111/joim.13343] [Reference Citation Analysis]
12 Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut 2021;69:1691-705. [DOI: 10.1136/gutjnl-2020-320622] [Cited by in Crossref: 53] [Cited by in F6Publishing: 59] [Article Influence: 26.5] [Reference Citation Analysis]
13 Liebe R, Keitel-anselmino V. Genetisches Risiko bei metabolischer Fettlebererkrankung: Gemeinsame Risikofaktoren für Fettlebererkrankung, Diabetes und Hyperlipidämie. Diabetologe 2020;16:552-9. [DOI: 10.1007/s11428-020-00647-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Targher G, Corey KE, Byrne CD. NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment. Diabetes Metab 2021;47:101215. [PMID: 33296704 DOI: 10.1016/j.diabet.2020.101215] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
15 Yang Y, Yang X, Lin Y, Yang G, Li L. LASS2 regulates hepatocyte steatosis by interacting with NDUFS2/OXPHOS related proteins. Biochem Biophys Res Commun 2020;526:871-9. [PMID: 32279995 DOI: 10.1016/j.bbrc.2020.02.166] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Ismaiel A, Popa SL, Dumitrascu DL. Acute Coronary Syndromes and Nonalcoholic Fatty Liver Disease: "Un Affaire de Coeur". Can J Gastroenterol Hepatol 2020;2020:8825615. [PMID: 33313020 DOI: 10.1155/2020/8825615] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Guerra S, Mocciaro G, Gastaldelli A. "Adipose tissue insulin resistance and lipidome alterations are the characterizing factors of NASH". Eur J Clin Invest 2021;:e13695. [PMID: 34695228 DOI: 10.1111/eci.13695] [Reference Citation Analysis]
18 Whyte MB, Shojaee-Moradie F, Sharaf SE, Cuthbertson DJ, Kemp GJ, Barrett M, Jackson NC, Herring RA, Wright J, Thomas EL, Bell J, Umpleby AM. HDL-apoA-I kinetics in response to 16 wk of exercise training in men with nonalcoholic fatty liver disease. Am J Physiol Endocrinol Metab 2020;318:E839-47. [PMID: 32286882 DOI: 10.1152/ajpendo.00019.2020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
19 Sasson A, Kristoferson E, Batista R, McClung JA, Abraham NG, Peterson SJ. The pivotal role of heme Oxygenase-1 in reversing the pathophysiology and systemic complications of NAFLD. Arch Biochem Biophys 2021;697:108679. [PMID: 33248947 DOI: 10.1016/j.abb.2020.108679] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Roeb E. Excess Body Weight and Metabolic (Dysfunction)-Associated Fatty Liver Disease (MAFLD). Visc Med 2021;37:273-80. [PMID: 34540943 DOI: 10.1159/000515445] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Borén J, Adiels M, Björnson E, Matikainen N, Söderlund S, Rämö J, Henricsson M, Ripatti P, Ripatti S, Palotie A, Mancina RM, Ainola M, Hakkarainen A, Romeo S, Packard CJ, Taskinen MR. Effects of PNPLA3 I148M on hepatic lipid and very-low-density lipoprotein metabolism in humans. J Intern Med 2021. [PMID: 34411351 DOI: 10.1111/joim.13375] [Reference Citation Analysis]
22 Kozaczek M, Kong B, Bottje W, Hakkak R. Hepatic Proteomics Analysis of Nonalcoholic Fatty Liver Disease Obese Rat Model After Short- and Long-Term Soy Protein Isolate Feeding. J Med Food 2021. [PMID: 34883038 DOI: 10.1089/jmf.2021.0088] [Reference Citation Analysis]
23 Nelidova AV, Livzan MA, Nikolaev NA, Krolevets TS. Cardiovascular Diseases and Non-Alcoholic Fatty Liver Disease: Relationship and Pathogenetic Aspects of Pharmacotherapy. Racionalʹnaâ farmakoterapiâ v kardiologii 2022;17:880-8. [DOI: 10.20996/1819-6446-2021-12-14] [Reference Citation Analysis]
24 Simons PIHG, Cornelissen MEB, Valkenburg O, Onland-Moret NC, van der Schouw YT, Stehouwer CDA, Burgess S, Brouwers MCGJ. Causal relationship between polycystic ovary syndrome and coronary artery disease: A Mendelian randomisation study. Clin Endocrinol (Oxf) 2021. [PMID: 34524719 DOI: 10.1111/cen.14593] [Reference Citation Analysis]
25 Budd J, Cusi K. Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease. Curr Diab Rep 2020;20:59. [PMID: 33015726 DOI: 10.1007/s11892-020-01349-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
26 Tavaglione F, Targher G, Valenti L, Romeo S. Human and molecular genetics shed lights on fatty liver disease and diabetes conundrum. Endocrinol Diabetes Metab 2020;3:e00179. [PMID: 33102799 DOI: 10.1002/edm2.179] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
27 Dabravolski SA, Bezsonov EE, Baig MS, Popkova TV, Orekhov AN. Mitochondrial Lipid Homeostasis at the Crossroads of Liver and Heart Diseases. Int J Mol Sci 2021;22:6949. [PMID: 34203309 DOI: 10.3390/ijms22136949] [Reference Citation Analysis]
28 Kouvari M, Boutari C, Chrysohoou C, Fragkopoulou E, Antonopoulou S, Tousoulis D, Pitsavos C, Panagiotakos DB, Mantzoros CS; ATTICA study Investigators. Mediterranean diet is inversely associated with steatosis and fibrosis and decreases ten-year diabetes and cardiovascular risk in NAFLD subjects: Results from the ATTICA prospective cohort study. Clin Nutr 2021;40:3314-24. [PMID: 33234342 DOI: 10.1016/j.clnu.2020.10.058] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
29 Ismaiel A, Dumitrascu DL. Genetic predisposition in metabolic-dysfunction-associated fatty liver disease and cardiovascular outcomes-Systematic review. Eur J Clin Invest 2020;50:e13331. [PMID: 32589269 DOI: 10.1111/eci.13331] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
30 Elosua-Bayés I, Beloqui Ruiz Ó. Association between non alcoholic fatty liver disease, metabolic and vascular risk. Clin Investig Arterioscler 2020;32:200-5. [PMID: 32736892 DOI: 10.1016/j.arteri.2020.04.002] [Reference Citation Analysis]
31 Chiriac S, Stanciu C, Girleanu I, Cojocariu C, Sfarti C, Singeap AM, Cuciureanu T, Huiban L, Muzica CM, Zenovia S, Nastasa R, Trifan A. Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases: The Heart of the Matter. Can J Gastroenterol Hepatol 2021;2021:6696857. [PMID: 33505944 DOI: 10.1155/2021/6696857] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
32 Xia M, Ma S, Huang Q, Zeng H, Ge J, Xu W, Wu Q, Wu L, Li X, Ma H, Chen L, Li Q, Aleteng Q, Hu Y, He W, Pan B, Lin H, Zheng Y, Wang S, Tang H, Gao X. NAFLD-related gene polymorphisms and all-cause and cause-specific mortality in an Asian population: the Shanghai Changfeng Study. Aliment Pharmacol Ther 2022. [PMID: 35023183 DOI: 10.1111/apt.16772] [Reference Citation Analysis]
33 Dai H, Fu Q, Chen H, Zhang M, Sun M, Gu Y, Zhou N, Yang T. A novel numerical model of combination levels of C-peptide and insulin in coronary artery disease risk prediction. Math Biosci Eng 2021;18:2675-87. [PMID: 33892566 DOI: 10.3934/mbe.2021136] [Reference Citation Analysis]
34 Ranadive SM, Lofrano-Porto A, Soares EMKVK, Eagan L, Porto LGG, Smith DL. Low testosterone and cardiometabolic risks in a real-world study of US male firefighters. Sci Rep 2021;11:14189. [PMID: 34244582 DOI: 10.1038/s41598-021-93603-z] [Reference Citation Analysis]
35 Cusi K, Godinez Leiva E. Cardiovascular risk in patients with nonalcoholic fatty liver disease: looking at the liver to shield the heart. Curr Opin Lipidol 2020;31:364-6. [PMID: 33149083 DOI: 10.1097/MOL.0000000000000717] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
36 Borén J, Adiels M, Björnson E, Matikainen N, Söderlund S, Rämö J, Ståhlman M, Ripatti P, Ripatti S, Palotie A, Mancina RM, Hakkarainen A, Romeo S, Packard CJ, Taskinen MR. Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans. JCI Insight 2020;5:144079. [PMID: 33170809 DOI: 10.1172/jci.insight.144079] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
37 Muzurović E, Mikhailidis DP, Mantzoros C. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. Metabolism 2021;119:154770. [PMID: 33864798 DOI: 10.1016/j.metabol.2021.154770] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Niederseer D, Wernly B, Aigner E, Stickel F, Datz C. NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations. J Clin Med 2021;10:467. [PMID: 33530440 DOI: 10.3390/jcm10030467] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]